IPO first-day returns, offer price revisions, volatility, and form S-1 language

被引:268
|
作者
Loughran, Tim [1 ]
McDonald, Bill [1 ]
机构
[1] Univ Notre Dame, Mendoza Coll Business, Notre Dame, IN 46556 USA
关键词
IPOs; First-day returns; Bookbuilding; S-1; filings; Textual analysis; INITIAL PUBLIC OFFERINGS; STOCK-MARKET; UNDERWRITER REPUTATION; PARTIAL ADJUSTMENT; LITIGATION RISK; INFORMATION; DISCLOSURE; EARNINGS; EQUITY; ISSUES;
D O I
10.1016/j.jfineco.2013.02.017
中图分类号
F8 [财政、金融];
学科分类号
0202 ;
摘要
Form S-1 is the first SEC filing in the initial public offering (IPO) process. The tone of the S-1, in terms of its definitiveness in characterizing the firm's business strategy and operations, should affect investors' ability to value the IPO. We find that IPOs with high levels of uncertain text have higher first-day returns, absolute offer price revisions, and subsequent volatility. Our findings provide empirical evidence for the theoretical models of uncertainty, bookbuilding, and prospect theory. (C) 2013 Elsevier BAT. All rights reserved.
引用
收藏
页码:307 / 326
页数:20
相关论文
共 13 条
  • [1] Systematic risk, the tradeoff of leverage and IPO first-day returns
    Ben Aissia, Dorsaf
    Hellara, Narjess Skhiri
    REVIEW OF QUANTITATIVE FINANCE AND ACCOUNTING, 2019, 53 (01) : 239 - 256
  • [2] IPO first-day returns: resilience to monetary policy shocks
    Alsabah, Khaled
    REVIEW OF BEHAVIORAL FINANCE, 2025, 17 (02) : 365 - 382
  • [3] Systematic risk, the tradeoff of leverage and IPO first-day returns
    Dorsaf Ben Aissia
    Narjess Skhiri Hellara
    Review of Quantitative Finance and Accounting, 2019, 53 : 239 - 256
  • [4] Institutional environment, firm ownership, and IPO first-day returns: Evidence from China
    Chen, Yibiao
    Wang, Steven Shuye
    Li, Wei
    Sun, Qian
    Tong, Wilson H. S.
    JOURNAL OF CORPORATE FINANCE, 2015, 32 : 150 - 168
  • [5] IPO first-day returns: Skewness preference, investor sentiment and uncertainty underlying factors
    Ben Aissia, Dorsaf
    REVIEW OF FINANCIAL ECONOMICS, 2014, 23 (03) : 148 - 154
  • [6] Impact of Charismatic Leadership and Market Shares on IPO First-Day Returns: The Case of Technology Firms
    Yeung, Wing Him
    Wu, Yuanyuan
    Liu, Feiyuan
    GLOBAL BUSINESS REVIEW, 2018, 19 (04) : 859 - 872
  • [7] A phase II study of a combination treatment of alternate-day S-1 and lentinan as first-line chemotherapy for unresectable or recurrent gastric cancer
    Yoshino, S.
    Nishimura, T.
    Sakata, K.
    Yoshida, S.
    Furuya, T.
    Yamamoto, T.
    Kawaoka, T.
    Shimizu, R.
    Sato, T.
    Matoba, K.
    Morioka, H.
    Iida, M.
    Suzuki, N.
    Takeda, S.
    Ueno, T.
    Hazama, S.
    Nagano, H.
    ANNALS OF ONCOLOGY, 2016, 27 : 26 - 26
  • [8] Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer
    Hiroki Yamaue
    Sohei Satoi
    Takamasa Kanbe
    Motoki Miyazawa
    Masaji Tani
    Manabu Kawai
    Seiko Hirono
    Kenichi Okada
    Hiroaki Yanagimoto
    A-Hon Kwon
    Tomoyuki Mukouyama
    Hiroaki Tsunoda
    Kazuo Chijiiwa
    Jiro Ohuchida
    Jun Kato
    Kazuki Ueda
    Taketo Yamaguchi
    Shinichi Egawa
    Kazuhiko Hayashi
    Tetsuhiko Shirasaka
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 97 - 102
  • [9] Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer
    Yamaue, Hiroki
    Satoi, Sohei
    Kanbe, Takamasa
    Miyazawa, Motoki
    Tani, Masaji
    Kawai, Manabu
    Hirono, Seiko
    Okada, Kenichi
    Yanagimoto, Hiroaki
    Kwon, A-Hon
    Mukouyama, Tomoyuki
    Tsunoda, Hiroaki
    Chijiiwa, Kazuo
    Ohuchida, Jiro
    Kato, Jun
    Ueda, Kazuki
    Yamaguchi, Taketo
    Egawa, Shinichi
    Hayashi, Kazuhiko
    Shirasaka, Tetsuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 97 - 102
  • [10] Interim safety analysis of a randomized phase II trial comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with advanced pancreatic cancer
    Yanagimoto, Hiroaki
    Okusaka, Takuji
    Ishii, Hiroshi
    Furuse, Junji
    Ohkawa, Shinichi
    Fukutomi, Akira
    Ioka, Tatsuya
    Sho, Masayuki
    Nakamori, Shoji
    Kitano, Masayuki
    Sugimori, Kazuya
    Maguchi, Hiroyuki
    Imaoka, Hiroshi
    Baba, Hideo
    Shimizu, Atsushi
    Yokota, Isao
    Ohashi, Yasuo
    Yamaue, Hiroki
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)